Overview

Botulinum Toxin Market Introduction:

The global botulinum toxin market is assessed to value over US$ 8 billion by the end of 2027 and grow at a CAGR of over 7% during the forecast period of 2020-2027.

Injecting Botulinum toxin type A (BOTOX) into the affected muscles has been an effective method for treating hardened tissues preventing its damage. Basically, muscles that are responsible for gnathological-related diseases are restored. BOTOX is a natural protein produced by Clostridium botulinum, which is an anaerobic bacterium. It initiates the release of acetylcholine (ACH), which is a neurotransmitter responsible for activating glandular secretions and muscle contraction and administrating it results in tone reduction of the targeted muscle. This toxin A has several clinical applications includes Prophylaxis of headaches in adult patients with chronic migraine, bruxism, rhinitis, sialorrhea, crocodile tears (lacrimation), pain (most commonly neuralgic origin), hyperhidrosis, foot dystonia, axial dystonia, Writer's cramp (WC) and other occupational cramps.

Botulinum Toxin Market Overview:

Clinically botulinum is used for the treatment of strabismus and huge demand in cosmetic applications. Growing research activities expanded the scope of botulinum for the treatment of neurological conditions like spasticity, dystonia, tremor, and others. Along with this, recent research activities have concluded that botulinum is also used for autonomic disorders like hypersecretory disorders, detrusor sphincter, and others. The growing demand of botulinum in disease management led to the robust growth of the market. Further, the increasing importance of botulinum in chemo-denervation and dermal filling created huge demand among the general population. Along with this, the growing importance of aesthetics and personal appearance among the general population led to the robust growth of the market. All these factors led to the burgeoning growth of the market.

High spending capacity and huge demand aesthetics among the general population of developed economies fuelled the growth of the global market. Developed economies like North America and Europe account for more 60% of the market share. The US dominated the North America market due to high penetration among the general population and end-user segment. UK, Germany, France, and Italy dominated the European market. The Asia Pacific is the most opportunistic market space for market players due to the limited presence of manufacturers. It represented a fast-growing region during the forecast period. Latin America and Rest of World is a highly untapped market due to the limited presence of manufacturers and less adoption.

Botulinum Toxin market players include Merz Pharma GmbH & Co. KGaA, Allergan Plc, Galderma, Ipsen, Pfizer Inc, and others.

Botulinum Toxin Market

Botulinum Toxin Market Segmentation:

By Application

Clinical Application
Cosmetic Application

By End User

Hospitals
Cosmetic Centres
Outpatient Centres

By Region

North America
Latin America
Europe
Asia Pacific
Rest of the World

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the global Botulinum Toxin A Market by Application, by End User, by Region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core competencies